^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
dexamethasone injection
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Generic mfg.
Drug class:
Steroid receptor agonist, GCR agonist
Related drugs:
1d
Stellate Ganglion Block Versus Oral Medication in Treatment of Palmar Hyperhidrosis (clinicaltrials.gov)
P=N/A, N=46, Completed, Fayoum University | Recruiting --> Completed
Trial completion
|
dexamethasone • dexamethasone injection
1d
DEXA_PERIOP: How Many Dexamethasone Doses Should Be Given Perioperatively? (clinicaltrials.gov)
P4, N=339, Enrolling by invitation, Mayo Clinic | Recruiting --> Enrolling by invitation | Trial primary completion date: Jan 2026 --> Jan 2027
Enrollment status • Trial primary completion date
|
dexamethasone injection
2d
131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma (clinicaltrials.gov)
P2, N=62, Active, not recruiting, Pediatric Brain Tumor Consortium | Trial completion date: Oct 2030 --> Sep 2027 | Trial primary completion date: Oct 2029 --> Mar 2026
Trial completion date • Trial primary completion date
|
CD276 (CD276 Molecule)
|
Avastin (bevacizumab) • temozolomide • irinotecan • Omblastys (131I-omburtamab) • dexamethasone injection • ondansetron intravenous
3d
LS1781: Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia (clinicaltrials.gov)
P2, N=80, Recruiting, Mayo Clinic | Trial completion date: Mar 2026 --> Nov 2033 | Trial primary completion date: Dec 2025 --> Feb 2031
Trial completion date • Trial primary completion date
|
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • BCL2 (B-cell CLL/lymphoma 2) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • DNMT3A (DNA methyltransferase 1) • SF3B1 (Splicing Factor 3b Subunit 1) • TET2 (Tet Methylcytosine Dioxygenase 2) • SRSF2 (Serine and arginine rich splicing factor 2) • U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1) • CD4 (CD4 Molecule) • ZRSR2 (Zinc Finger CCCH-Type, RNA Binding Motif And Serine/Arginine Rich 2)
|
IDH2 mutation • TET2 mutation • SF3B1 mutation • EZH2 mutation • SRSF2 mutation
|
cisplatin • carboplatin • gemcitabine • Rituxan (rituximab) • cytarabine • cyclophosphamide • ifosfamide • oxaliplatin • etoposide IV • decitabine • Truxima (rituximab-abbs) • Hemady (dexamethasone tablets) • Mabtas (rituximab biosimilar) • Starasid (cytarabine ocfosfate) • dexamethasone injection
4d
Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial (clinicaltrials.gov)
P2, N=17, Active, not recruiting, Mayo Clinic | Recruiting --> Active, not recruiting | N=75 --> 17
Enrollment closed • Enrollment change
|
TP53 (Tumor protein P53)
|
TP53 mutation
|
lenalidomide • carfilzomib • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Hemady (dexamethasone tablets) • dexamethasone injection
4d
GMMG-HD7: Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7) (clinicaltrials.gov)
P3, N=662, Active, not recruiting, University of Heidelberg Medical Center | Trial completion date: Mar 2027 --> Jun 2028 | Trial primary completion date: May 2025 --> Jun 2028
Trial completion date • Trial primary completion date
|
lenalidomide • bortezomib • doxorubicin hydrochloride • cyclophosphamide • dexamethasone • Sarclisa (isatuximab-irfc) • dexamethasone injection
4d
PA: Prophylactic Dexamethasone Before Infliximab in Moderate-to-Severe IBD (clinicaltrials.gov)
P=N/A, N=300, Recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University
New trial
|
dexamethasone injection
5d
Impact of Dexamethasone Route on Pain and Inflammation in iPACK With ACB for Knee Arthroplasty (clinicaltrials.gov)
P4, N=90, Recruiting, Poznan University of Medical Sciences | Trial completion date: Oct 2025 --> Oct 2026 | Trial primary completion date: Sep 2025 --> Sep 2026
Trial completion date • Trial primary completion date
|
dexamethasone injection
5d
Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies (clinicaltrials.gov)
P1, N=27, Recruiting, Abdullah Khan | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
Trial completion date • Trial primary completion date • IO biomarker
|
IKZF1 (IKAROS Family Zinc Finger 1) • CRBN (Cereblon)
|
Empliciti (elotuzumab) • Hemady (dexamethasone tablets) • mezigdomide (CC-92480) • dexamethasone injection
7d
The Effect of Corticosteroids on Quality of Life Following Total Hip Arthroplasty: HIPSTER Study (clinicaltrials.gov)
P4, N=224, Not yet recruiting, Ziekenhuis Oost-Limburg
New P4 trial • HEOR
|
dexamethasone injection
8d
A Single-Center Prospective Randomized Controlled Clinical Study Evaluating the Efficacy of High-Dose Dexamethasone Followed by Sequential Prednisone Maintenance Therapy in Adults with Newly Diagnosed Immune Thrombocytopenia (ChiCTR2600117105)
P=N/A, N=170, Not yet recruiting, Nanjing Drum Tower Hospital; Nanjing Drum Tower Hospital
New trial
|
Rituxan (rituximab) • prednisone • dexamethasone injection
8d
Comparison of the Efficacy and Safety of Dexamethasone Palmitic Acid Injection and Compound Betamethasone Injection in Soft Tissue Interventional Therapy for Acute and Chronic Painful Diseases (ChiCTR2600116219)
P=N/A, N=334, Recruiting, Zhejiang Provincial Hospital of TCM; Zhejiang Provincial Hospital of TCM
New trial
|
dexamethasone injection
Share via
